Neurocrine BiosciencesNBIX
NBIX
About: Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Employees: 1,700
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
25% more funds holding in top 10
Funds holding in top 10: 8 [Q2] → 10 (+2) [Q3]
18% more repeat investments, than reductions
Existing positions increased: 232 | Existing positions reduced: 196
8% more call options, than puts
Call options by funds: $83.4M | Put options by funds: $77.4M
3.76% less ownership
Funds ownership: 97.04% [Q2] → 93.29% (-3.76%) [Q3]
4% less funds holding
Funds holding: 585 [Q2] → 562 (-23) [Q3]
19% less first-time investments, than exits
New positions opened: 69 | Existing positions closed: 85
19% less capital invested
Capital invested by funds: $13.4B [Q2] → $10.9B (-$2.58B) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$148
3%
upside
Avg. target
$165
15%
upside
High target
$190
33%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
UBS Ashwani Verma 58% 1-year accuracy 11 / 19 met price target | 13%upside $162 | Buy Maintained | 8 Jan 2025 |
Piper Sandler David Amsellem 58% 1-year accuracy 23 / 40 met price target | 12%upside $160 | Overweight Reiterated | 23 Dec 2024 |
Barclays Carter Gould 35% 1-year accuracy 13 / 37 met price target | 15%upside $165 | Overweight Maintained | 23 Dec 2024 |
Wedbush Laura Chico 25% 1-year accuracy 15 / 61 met price target | 3%upside $148 | Outperform Reiterated | 16 Dec 2024 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 109 / 339 met price target | 33%upside $190 | Buy Reiterated | 16 Dec 2024 |
Financial journalist opinion
Based on 3 articles about NBIX published over the past 30 days
Neutral
GlobeNewsWire
6 days ago
Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio
Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”) regarding the clinical development of its partnered muscarinic agonist portfolio. These updates were presented by Neurocrine at the 43rd Annual J.P. Morgan Healthcare Conference. The update presented by Neurocrine included the following information:
Neutral
PRNewsWire
1 week ago
Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
Narrative Review Assesses Current Treatment Challenges and the Evolving Classic Congenital Adrenal Hyperplasia (CAH) Therapeutic Landscape Non-Glucocorticoid (GC) Mechanisms for Treatment of CAH Could Enable Control of Excess ACTH and Androgens Without the Need for High-Dose GCs, Reducing Related Complications Over a Lifetime SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a narrative review discussing the challenges of traditional treatment of classic congenital adrenal hyperplasia (CAH) with glucocorticoids (GCs) alone and the potential benefits of introducing novel non-GC mechanisms for treating the condition that may enable lower, more physiologic GC dosing. The publication appears in Expert Review of Endocrinology & Metabolism.
Neutral
PRNewsWire
2 weeks ago
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m.
Neutral
PRNewsWire
1 month ago
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S. CAH-trained pharmacists are available 24/7 to support patients with prescriptions exclusively through PANTHERx Rare, a specialty pharmacy Neurocrine Access Support is available to provide free, comprehensive access and support information to patients, caregivers and healthcare providers SAN DIEGO , Dec. 20, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced CRENESSITY™ (crinecerfont) is now commercially available in the United States. CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH).
Positive
Seeking Alpha
1 month ago
Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth
Neurocrine's Ingrezza is forecasted to generate $2.3 billion in revenue in 2024, cementing its role as the company's primary revenue driver. Crenessity's approval for CAH treatment represents a transformative opportunity. Peak sales are estimated at $1.47 billion by 2030. Neurocrine's pipeline includes five Phase 1, six Phase 2, and two Phase 3 programs, diversifying future growth opportunities.
Positive
Investors Business Daily
1 month ago
Neurocrine Wins FDA Approval For Genetic Disorder Drug
Neurocrine Biosciences won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades. The post Neurocrine Wins FDA Approval For Genetic Disorder Drug appeared first on Investor's Business Daily.
Neutral
PRNewsWire
1 month ago
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH CRENESSITY is expected to be commercially available in approximately one week Rare Pediatric Disease Priority Review Voucher granted in connection with approval SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITY™ (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction.
Positive
Reuters
1 month ago
US FDA approves Neurocrine Biosciences' genetic disorder drug
The U.S. Food and Drug Administration has approved Neurocrine Biosciences' drug to treat a type of genetic disorder, the health regulator's website showed on Friday.
Neutral
PRNewsWire
1 month ago
Neurocrine Biosciences to Participate at Investor Conferences in December
The 7th Annual Evercore HealthCONx Conference on December 3 Citi's 2024 Global Healthcare Conference on December 4 SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in December. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Vice-President of Investor Relations Todd Tushla will present at: The 7th Annual Evercore HealthCONx Conference at 10:50 a.m.
Positive
Seeking Alpha
2 months ago
Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels
Neurocrine Biosciences, Inc.'s August share price decline after the messy phase 2 results of NBI-568 in schizophrenia patients is understandable, but the magnitude is not. Neurocrine is trading at slow growth big pharma multiples, not at multiples of a company with significant growth potential that it is. Ingrezza continues to deliver strong growth and cash flows for the company, and crinecerfont will be launched in early 2025.
Charts implemented using Lightweight Charts™